High-dose recombinant interleukin-2/verapamil combination in advanced cancer [2]

European Journal of Cancer Part A

Volumn 32, Issue 8, 1996, Pages 1436-1437

  Tagliaferri, P ^a   Correale, P ^a   Mottola, M ^a   De Simone, G ^a   Montesarchio, V ^a   Matano, E ^a   Rea, A ^a   Morabito, A ^a   Famiani, M ^a   Ciardiello, F ^a   Tortora, G ^a   Caraglia, M ^a   Barile, C ^a   Palmieri, G ^a   Bianco, A R ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2; VERAPAMIL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ATRIOVENTRICULAR BLOCK; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; FEMALE; HEART ARRHYTHMIA; HUMAN; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; LETTER; MALE; NAUSEA; OLIGURIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030056812     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00126-8     Document Type: Letter

References (8)

1. Rosenberg SA, Lotze MT, Yang J, et al. Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989, 210, 474-483.
2. Lotze MT, Matory SE, Ettinghausen SE, et al. In vivo administration of purified recombinant interleukin-2. II. Half life, immunological effects and expansion of peripheral lymphoid cells with recombinant IL-2. J Immunol 1985, 135, 2865-2875.
3. Hank JA, Kohler PC, Weill-Hillman G. In vivo induction of the lymphokine activated killer phenomenon: interleukin-2 dependent human non-major histocompatibility complex restricted cytotoxicity generated in vivo during administration of human recombinant interleukin-2. Cancer Res 1988, 48, 1965-1971.
4. Grimm EA, Mazumber A, Zhang HZ, et al. Lymphocyte activated killing phenomenon: lysis of natural killer resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982, 155, 1823-1841.
5. Correale P, Tagliaferri P, Celio L, et al. Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK cytotoxicity in vitro. Eur J Cancer 1991, 27A, 1393-1395.
6. Pennock GD, Dalton WS, Roeske WR. Systemic toxic effects associated to high dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 1991, 83, 105-110.
7. Negrier S, Philip T, Stoter G. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur J Cancer Clin Oncol 1989, 25 (Suppl. 3), 21-28.
8. Gaynor ER, Weiss GR, Margolin KA, et al. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. J Natl Cancer Inst 1990, 82, 1397-1402.